Compositions and Methods for Treating Cancer with DuoCARs
AssigneeLentigen Technology, Inc.
InventorsRimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
Life of this patent
Estimating the term…
Abstract
Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
Claims13
-22. (canceled)
A pharmaceutical composition comprising an antitumor effective amount of a population of human natural killer (NK) cells, wherein the NK cells of the population include NK cells comprising one or more multicistronic vectors;
- wherein each multicistronic vector encodes a functional chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO:
- 110, 112, 114, or 116.
-32. (canceled)
A method of treating a subject having a cancer, the method comprising administering to the subject a pharmaceutical composition comprising an antitumor effective amount of a population of human NK cells, wherein the population of human NK cells comprises NK cells comprising two or more vectors;
- wherein each vector encodes a functional CAR comprising the amino acid sequence of SEQ ID NO:
- 110, 112, 114, or 116.
(canceled)
-38. (canceled)
Dependencies are inferred from the claim text.